Naarden-based Phlox Therapeutics, a biotechnology company, has raised €1.9M in funding to advance its RNA therapies for genetic laminopathies.
The funding round adds ROM Utrecht Region to its existing investor syndicate, which includes FIRST Fund (managed by BGV), Amsterdam UMC Venture Holding, and Utrecht Health Seed Fund (UHSF).
Additionally, non-dilutive investment from the Dutch Research Council (NWO) and a public-private partnership with the Hubrecht Institute, supported by Health~Holland, further strengthen Phlox’s financial position.
What does Phlox Therapeutics offer?
Founded in 2022 by Yigal Pinto and Eva van Rooij, Phlox Therapeutics is developing Ribonucleic acid (RNA)-based gene therapies to treat cardiomyopathies, disorders that affect the heart muscle.
The company focuses on targeting genetic mutations associated with these conditions, aiming to improve outcomes for patients who have limited treatment options with the current standard of care.
By advancing its RNA technology, Phlox positions itself as a key player in next-generation RNA therapies for genetic heart diseases.
Adinda Woelderink, Investment Manager at ROM Utrecht Region, says, “We are excited to support Phlox Therapeutics in its groundbreaking work developing RNA therapies for cardiomyopathies.”
“Their approach to addressing currently untreatable genetic laminopathies holds great promise, and we believe this funding will play a critical role in driving their lead program further into preclinical development.”
Capital utilisation
Phlox Therapeutics has secured funding to support the preclinical development of its lead program, which targets genetic diseases associated with the lamin protein.
The combination of investment and non-dilutive funding will help advance Phlox’s development pipeline and further its work in pioneering RNA therapies for genetic heart diseases.
Prof. Eva van Rooij, Phlox Therapeutics’ CSO, adds, “The Phlox’s team is delighted to have the support of this syndicate of investors. The public-private partnership with the Hubrecht Institute, combined with the additional support from Health~Holland, allows us to accelerate our preclinical work and simultaneously deepen our scientific understanding of cardio-myopathies.”
“We are eager to move closer to clinical applications that could benefit patients with these life-threatening conditions.”
01
Not solo: How Xolo aims to help Dutch solopreneurs with its comprehensive business management platform